Zolbetuximab is a targeted therapeutic drug directed against CLDN18.2, and it has attracted significant attention in the field of gastric cancer treatment. It has been launched in China but is not included in China's national medical insurance scheme. Currently, there are no generic versions of this drug available on the market, meaning patients have to bear the full cost of treatment, which is quite high. The original research drug produced by Astellas Pharma Inc. of Japan is priced at approximately 1,482 US dollars per box.
What is the Price of Zolbetuximab?
The price of Zolbetuximab varies depending on factors such as the region, sales channel, and purchase quantity.
Price of the Original Research Drug
The original research drug is manufactured by Astellas Pharma Inc. (Japan). For the specification of 100mg/vial, the price of the original research drug is approximately 1,482 US dollars per box in the international market. This price is for reference only, and the actual purchase price may fluctuate due to various factors. As zolbetuximab has not been officially launched in China yet, patients may need to obtain the drug through channels such as overseas drug purchasing or participation in clinical trials.
Analysis of Factors Affecting the Price
The price of zolbetuximab is influenced by multiple factors. The level of economic development, medical policies, and market competition in different regions can all have an impact on its price. Additionally, factors like the purchase quantity, procurement channel, and whether one participates in government procurement projects may also lead to price differences. When purchasing zolbetuximab, patients should fully understand relevant information to make informed decisions.
Package Insert of Zolbetuximab
The package insert of zolbetuximab is an important resource for patients and medical staff to learn about the drug, and it plays a crucial role in guiding the rational use of the drug by patients.
Indications, Dosage and Administration
Zolbetuximab is indicated for the treatment of unresectable advanced or recurrent gastric cancer positive for Claudin 18.2 (CLDN18.2). For adult patients, the recommended initial dose is 800mg/m². For the second and subsequent doses, the dosage can be reduced to 600mg/m², and after an interval of 3 weeks, it can be further reduced to 400mg/m². The drug is administered via intravenous infusion over a period of more than 2 hours, with an interval of every 2 weeks.
Adverse Reactions and Precautions
Zolbetuximab may cause adverse reactions such as allergic reactions, severe nausea, and vomiting. During the use of this drug, patients should pay close attention to their physical condition and seek medical attention promptly if any uncomfortable symptoms occur.
Precautions for the Administration of Zolbetuximab
Both patients and medical staff need to adhere to certain precautions when administering zolbetuximab.
Reconstitution and Dilution Process
Zolbetuximab must be reconstituted using water for injection as specified in the Japanese Pharmacopoeia. During reconstitution, aseptic conditions must be maintained. Water for injection should be slowly injected along the inner wall of the vial; shaking is not allowed, and the solution should be gently stirred until it is completely dissolved. After reconstitution, the solution should be allowed to stand to let air bubbles disappear before dilution. The diluted drug should be used promptly, and under room temperature conditions, the diluted drug must be administered within 6 hours.
Administration Guidance for Special Populations
For special populations such as pregnant women, lactating women, and children, the administration of zolbetuximab requires caution. Pregnant women are only advised to use this drug if the potential benefits of treatment are considered to outweigh the risks of the disease itself, and it must be used under the guidance of a doctor. Lactating women are not recommended to breastfeed during the period of using this drug. Due to the lack of clinical trial data in children, this drug should also be used with caution in children under the guidance of a doctor.
During the use of zolbetuximab, patients should also note that they should avoid using the same infusion line for administering other drugs simultaneously, to prevent the occurrence of drug interactions.
